Browse

You are looking at 1 - 4 of 4 items for

  • By Author: Boldrey, Edwin B. x
  • By Author: Wilson, Charles B. x
Clear All
Restricted access

John Calogero, David C. Crafts, Charles B. Wilson, Edwin B. Boldrey, Alan Rosenberg and K. Jean Enot

✓The authors present three patients who, after excision and irradiation of their brain tumors, were treated with BCNU for recurrence. All three patients responded well and now are without evidence of tumor, 37, 30, and 36 months after BCNU was stopped. Although these patients represent only a small fraction of those treated with BCNU, they indicate the potential role of chemotherapy in the management of glial tumors.

Restricted access

A. R. Vasantha Kumar, Justin Renaudin, Charles B. Wilson, Edwin B. Boldrey, K. Jean Enot and Victor A. Levin

✓ A series of 43 patients, all of whom were deteriorating due to progression of primary or metastatic brain tumors, were treated daily with n-isopropyl-α-(2-methylhydrazine)-p-toluamide hydrochloride (matulane, Procarbazine hydrochloride: NSC-77213, 150 mg./m2) for 30 consecutive days, with a 30-day rest interval between treatments. Of 29 patients evaluated, 12 showed a definite clinical response to therapy and two a probable response, for a response rate of 48%. Reversible myelosuppression was the major toxic effect encountered. Combination with other chemotherapeutic agents may enhance the drug's effectiveness against brain tumors.

Restricted access

Anthony D. Oliver, Charles B. Wilson and Edwin B. Boldrey

✓ Two cases of spinal arteriovenous malformation (AVM) are reported because of a previously unobserved clinical feature: recurrent transient postprandial paresis of the legs. The authors believe the paresis was caused by chronic shunting of blood away from the cord and into the low-resistance AVM. Symptomatic cord ischemia might then be precipitated by vasodilatation in other areas of the body such as the splanchnic, brachial, or uterine vessels. We believe that in some instances this mechanism should be considered as an explanation for episodic neurological deficits seen in association with spinal AVM's.

Restricted access

Justin Renaudin, Derek Fewer, Charles B. Wilson, Edwin B. Boldrey, John Calogero and K. Jean Enot

✓ Twenty patients seriously ill following subtotal excision of brain tumors were given unusually large doses of Decadron to restrain peritumoral edema. The prompt clinical effect was strikingly favorable in 11. The dosage of Decadron above which no additional anti-edema effect occurs must be established for each individual patient. No significant complications occurred under dosages ranging from 32 to 96 mg/day. Brain scintiscans performed after rapid clinical improvement in five cases showed no change.